Head to Head Comparison: TransEnterix (TRXDW) versus Its Peers

TransEnterix lags rivals in revenue and earnings, but trades at a lower valuation

Mar. 11, 2026 at 12:27am

Got story updates? Submit your updates here. ›

This article compares the financial performance and valuation of TransEnterix, a medical device company, against its industry peers. The data shows that TransEnterix's rivals have higher revenue and earnings per share, but TransEnterix is trading at a lower price-to-earnings ratio, indicating it is more affordable. TransEnterix also has a higher beta, meaning its share price is more volatile than the average of its competitors.

Why it matters

This comparison provides insight into TransEnterix's competitive positioning within the medical device robotics industry. While TransEnterix lags its peers in some key financial metrics, its lower valuation could make it an attractive investment option for some investors looking for a potentially undervalued stock in this sector.

The details

The data shows that TransEnterix's revenue is $8.53 million, while its rivals have higher revenue. TransEnterix also has negative net income of $154.20 million, compared to its competitors who have positive earnings. In terms of valuation, TransEnterix is trading at a lower price-to-earnings ratio than its peers. However, TransEnterix has a higher beta of 2.56, indicating its share price is more volatile than the average of its rivals, which have a beta of 1.80.

  • The financial data is as of March 11, 2026.

The players

TransEnterix, Inc.

A medical device company that engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers the Senhance System, a multi-port robotic surgery system, and is headquartered in Morrisville, North Carolina.

Got photos? Submit your photos here. ›

The takeaway

This comparison highlights that while TransEnterix lags its peers in some key financial metrics, its lower valuation could make it an attractive investment option for investors seeking exposure to the medical device robotics industry. However, the company's higher volatility relative to its competitors is an important factor to consider.